Adoption of revolutionary procedure for left ventricular reconstruction spreads across Europe

13 November 2013

BioVentrix Announces 50th Clinical Case Milestone for Revivent Technology

Adoption of revolutionary procedure for left ventricular reconstruction spreads across Europe

AALST, Belgium -- BioVentrix, a pioneer of technologies and procedures for less-invasive treatment of heart failure (HF), today announced the successful completion of it 50th clinical case using the Revivent™ Myocardial Anchoring System in a 74-year-old male patient at the OLV Hospital in Aalst, Belgium. The case comes on the heels of other successful cases performed recently in Germany, Italy, and the UK.

Performed by OLV staff surgeons Filip Casselman, M.D., Ph.D., and Bernard Stockman, M.D., the case marks the first time that the Less Invasive Ventricular Enhancement™ or LIVE™ procedure has been performed in Belgium. Recognized as a top-tier research facility, OLV is particularly well-known for its adoption of groundbreaking technology in the fields of cardiology and cardiovascular surgery.

"OLV remains at the forefront of implementing promising less-invasive surgical technologies to address the overwhelming need for better heart failure treatment options,” said Dr. Casselman. “The adoption of the Revivent System allows us to treat the underlying cause of heart failure by reshaping the left ventricle of the heart to operate more efficiently. Immediately after placement of the device, the patient’s ejection fraction, the most revealing measure of heart function, had already improved.”

Prior to the Revivent System, reshaping of the left ventricle used an invasive procedure known as surgical ventricular reconstruction (SVR) to remove the scarred, non-functioning tissue created by a heart attack. The invasive nature of SVR limits its use because it requires stopping the patient’s heart and supporting it with cardiopulmonary (heart-lung) bypass while incisions into the heart muscle are made to remove the tissue. Placement of the Revivent System via the LIVE procedure obviates these requirements. Instead, small titanium anchors are placed along the outer surface of the heart and along one of the interior walls. The anchors are then pulled toward one another, effectively excluding the scarred, and non-functioning heart wall. The efficiency of the remaining heart muscle is immediately improved, by as much as 30-40 percent.In 92 percent of patients, the efficacy results were durable beyond one year.

“The LIVE procedure and the Revivent System have gained a foothold in Western Europe, because it is the only technology that stops the destructive, ongoing process of heart failure,” said David Schickling, vice president of sales and marketing at BioVentrix. “We are gratified that our technology is immediately impacting the lives of patients and their families by allowing them to regain a significantly improved quality of life.”

The Revivent Myocardial Anchoring System is CE marked and approved for sale in Europe.

« Go back